Adjunctive Corticosteroids for Pneumocystis jirovecii Pneumonia in Non-HIV-Infected Patients: A Systematic Review and Meta-Analysis of Observational Studies

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Archivos De Bronconeumologia

• Publication date

  2017-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.ARBR.2016.08.002
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection.

  2015cited by this paper
• Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.

  2014cited by this paper
• Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients.

  2014cited by this paper
• Outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative patients.

  2014cited by this paper
• Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection.

  2014cited by this paper
• Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies

  2012cited by this paper
• Analysis of clinical features of non-HIV Pneumocystis jirovecii pneumonia

  2012cited by this paper
• Outcomes of Moderate-to-Severe Pneumocystis Pneumonia Treated with Adjunctive Steroid in Non-HIV-Infected Patients

  2011cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection

  2008cited by this paper
• Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients.

  2007cited by this paper
• Prevention of Infection Due to Pneumocystis spp. in Human Immunodeficiency Virus-Negative Immunocompromised Patients

  2004cited by this paper
• Consensus Statement

  2004cited by this paper
• Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: A strategy for prevention

  2004cited by this paper
• Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study.

  2003cited by this paper
• Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome.

  2002cited by this paper
• Analysis of Underlying Diseases and Prognosis Factors Associated with Pneumocystis carinii Pneumonia in Immunocompromised HIV-Negative Patients

  2002cited by this paper
• Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients.

  1999cited by this paper
• Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia.

  1998cited by this paper
• Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy.

  1996cited by this paper
• Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases.

  1995cited by this paper
• Prevention and treatment of pneumocystis pneumonia.

  1992cited by this paper
• Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome.

  1990cited by this paper

• Global prevalence, mortality, and main risk factors for COVID-19 associated pneumocystosis: A systematic review and meta-analysis

  2022cites this paper
• Characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with idiopathic membranous nephropathy

  2021cites this paper
• Neumonía por Pneumocystis Jirovecii en paciente adolescente inmunosuprimido no VIH positivo: Un reporte de caso

  2020cites this paper
• Immunotherapy against Systemic Fungal Infections Based on Monoclonal Antibodies

  2020cites this paper
• Use of glucocorticoids in the critical care setting: science and clinical evidence.

  2020cites this paper
• Combination Immunotherapy with Passive Antibody and Sulfasalazine Accelerates Fungal Clearance and Promotes the Resolution of Pneumocystis-Associated Immunopathogenesis

  2019cites this paper
• Clinical Syndromes: Pneumocystis

  2018cites this paper